BIOMARKERS FOR THE DETECTION OF EARLY STAGE OVARIAN CANCER
The present invention provides methods and compositions for detecting early stage ovarian cancer in a patient. Also, methods for evaluating the ovarian cancer state of a patient are described herein. These methods involve the detection, analysis, and classification of biomarkers in biological samples.
1 . (canceled)
2 . A method of determining if a patient has early stage ovarian cancer comprising:
(a) determining the concentration/expression levels/peak intensity values of a combination of biomarkers in a sample from the subject, wherein the biomarkers comprise: (i) apolipoprotein A1 (ApoA1), (ii) transthyretin (TTR), (iii) CTAPIII, (iv) CA 125, and transferrin; and
(b) correlating the measurement with ovarian cancer status
3 . The method of claim 2 , wherein the early stage ovarian cancer is stage I ovarian cancer.
4 . The method of claim 2 , wherein the early stage ovarian cancer is stage II ovarian cancer
5 . The method of claim 1 further comprising:
(c) managing subject treatment based on the status.
6 . The method of claim 5 , wherein managing subject treatment is selected from ordering more tests, performing surgery, and taking no further action.
7 . The method of claim 6 further comprising:
(d) determining the m/z values for the panel of biomarkers after subject management.
8 - 12 . (canceled)
13 . The method of claim 1 wherein the panel of biomarkers are measured using a biochip array.
14 . The method of claim 13 wherein the biochip array is a protein chip array.
15 . The method of claim 14 wherein the biochip array is a nucleic acid array.
16 . The method of claim 15 wherein the panel of biomarkers are immobilized on the biochip array.
17 . The method of claim 1 wherein the panel of protein biomarkers are measured by SELDI.
18 . The method of claim 1 wherein the panel of protein biomarkers are measured by immunoassay.
19 . The method of claim 1 wherein the correlating is performed by a software classification algorithm.
20 . The method of claim 1 wherein the sample is selected from blood, serum and plasma.
21 . A kit comprising:
(a) a capture reagent that binds a panel of biomarkers comprising (i) apolipoprotein A1 (ApoA1), (ii) transthyretin (TTR), (iii) transferrin (TFR), and (iv) CA 125; and
(b) a container comprising at the panel of biomarkers.
22 . A kit comprising:
(a) a capture reagent that binds a panel of biomarkers comprising (i) apolipoprotein A1 (ApoA1), (ii) transthyretin (TTR), (iii) CTAPIII, and (iv) CA 125; and
(b) a container comprising at the panel of biomarkers.
23 . The kit of claim 21 wherein the capture reagents binds a plurality of the biomarkers.
24 . The kit of claim 21 wherein the capture reagents are SELDI probes.
25 . The kit of claim 21 wherein the capture reagents are an immobilized metal chelate.
26 . The kit of claim 21 further comprising a wash solution that selectively allows retention of the bound biomarker to the capture reagent as compared with other biomarkers after washing.
27 . (canceled)